NEW YORK – In spite of the company's recent acquisition of GenePOC in an effort to fortify its diagnostics business, Meridian Bioscience's CEO said on Tuesday that it could be more than a year before that business reverses its slide.
On Tuesday, the Cincinnati-based firm announced a 6 percent drop in revenues year-over-year for its fiscal third quarter, with a 9 percent decline in its diagnostics business, driven primarily by a 21 percent decline in molecular diagnostics.